Active Filter(s):
Details:
The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).
Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Midas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2021
Details:
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).
Lead Product(s): Candesartan Cilexetil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Divestment January 04, 2021
Details:
AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.
Lead Product(s): Candesartan Cilexetil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Divestment October 30, 2020